Amphastar Pharmaceuticals, Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Amphastar Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2021-09-30 was $3.87M.
- Amphastar Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $10.97M, a 29.91% decline from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $15.66M, a 1.68% decline from fiscal 2021.
- Amphastar Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2021 was $15.93M, a 31.25% decline from fiscal 2020.
- Amphastar Pharmaceuticals, Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2020 was $23.16M, a 577.14% increase from fiscal 2019.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2023-12-31 | $10.97M 10-K · filed 2024-02-29 | |
| 2022-12-31 | $15.66M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $15.93M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $3.87M 10-Q · filed 2021-11-09 | |
| 2020-12-31 | $23.16M 10-K · filed 2023-03-01 | |
| 2019-12-31 | $3.42M 10-K · filed 2022-03-11 | |
| 2018-12-31 | $8.95M 10-K · filed 2021-03-15 | |
| 2017-12-31 | $13.76M 10-K · filed 2020-03-16 | |
| 2016-12-31 | $20.64M 10-K · filed 2019-03-15 | |
| 2015-12-31 | $14.20M 10-K · filed 2018-03-14 | |
| 2014-12-31 | $182.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |